These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20140880)

  • 41. Response adaptive designs with a variance-penalized criterion.
    Yi Y; Wang X
    Biom J; 2009 Oct; 51(5):763-73. PubMed ID: 19757432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Precision of maximum likelihood estimation in adaptive designs.
    Graf AC; Gutjahr G; Brannath W
    Stat Med; 2016 Mar; 35(6):922-41. PubMed ID: 26459506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
    Masaki N; Koyama T; Yoshimura I; Hamada C
    J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimal adaptive two-stage designs for early phase II clinical trials.
    Shan G; Wilding GE; Hutson AD; Gerstenberger S
    Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identifying combined design and analysis procedures in two-stage trials with a binary end point.
    Bowden J; Wason J
    Stat Med; 2012 Dec; 31(29):3874-84. PubMed ID: 22786815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two-stage designs for phase II cancer trials with ordinal responses.
    Stallard N; Cockey L
    Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bias reduction in logistic dose-response models.
    Wagler A
    J Biopharm Stat; 2011 May; 21(3):405-22. PubMed ID: 21442516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimating the response rate in the presence of measurement error.
    Qu Y; Kulkarni PM; Sanger TM
    Stat Med; 2007 Jan; 26(1):197-211. PubMed ID: 16526011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selection and bias--two hostile brothers.
    Bauer P; Koenig F; Brannath W; Posch M
    Stat Med; 2010 Jan; 29(1):1-13. PubMed ID: 19844944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A restricted maximum likelihood estimator for truncated height samples.
    A'Hearn B
    Econ Hum Biol; 2004 Mar; 2(1):5-19. PubMed ID: 15463990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Testing for treatment effect in the presence of regression toward the mean.
    George V; Johnson WD; Shahane A; Nick TG
    Biometrics; 1997 Mar; 53(1):49-59. PubMed ID: 9147603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
    Sposto R; Gaynon PS
    Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.
    Zhao J; Yu M; Feng XP
    BMC Med Res Methodol; 2015 Jun; 15():48. PubMed ID: 26048655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimal design for dose response using beta distributed responses.
    Wu Y; Fedorov VV; Propert KJ
    J Biopharm Stat; 2005; 15(5):753-71. PubMed ID: 16078383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sample size and optimal designs in stratified comparative trials to establish the equivalence of treatment effects among two ethnic groups.
    Chen YH; Wang M
    J Biopharm Stat; 2002 Nov; 12(4):553-66. PubMed ID: 12477074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.